Regeneron Pharmaceuticals reports $4.29 billion revenue for quarter ended June 30, 2026, up 16.7%

ยท REGN

Regeneron Pharmaceuticals reported revenue of $4.29 billion for the quarter ended June 30, 2026, an increase of 16.7% from the same quarter a year earlier ($3.68 billion).

For the same period it posted net income of $1.3 billion, down 6.8%, or $12.23 per diluted share (12.81 a year earlier).

That is a net margin of 30.2%.

On Sanad's AAOIFI Standard 21 screen, Regeneron Pharmaceuticals is currently questionable: interest-bearing debt is 2.7% of market capitalisation (limit 30%), and impure income is 4.4% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on July 30, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Regeneron Pharmaceuticals news